Tags

Type your tag names separated by a space and hit enter

The duration of response to norgestimate and ethinyl estradiol in the treatment of acne vulgaris.
Int J Fertil Womens Med. 1998 Nov-Dec; 43(6):286-90.IJ

Abstract

OBJECTIVE

This was a postmarketing, retrospective, exploratory analysis to investigate the duration of response to a triphasic combination oral contraceptive (OC) (Ortho Tri-Cyclen; Ortho-McNeil Pharmaceutical, Raritan, NJ) [norgestimate-ethinyl estradiol]) in the treatment of moderate acne vulgaris.

PROCEDURES

Healthy women with moderate acne vulgaris were enrolled in two 6-month, multicenter, randomized, double-blind, placebo-controlled clinical trials. Subjects received either 3 weeks of active OC treatment (i.e., 0.035 mg ethinyl estradiol plus increasing doses of norgestimate [0.180 mg, 0.215 mg, 0.250 mg]) and 1 week of inactive tablets, or 4 weeks of color-matched placebo tablets.

RESULTS

A total of 507 subjects were enrolled in the study. Duration of response was analyzed in subjects with at least slight improvement in global progress of treatment from the earliest cycle showing response (n = 305) and in subjects with at least slight improvement at or before cycle 3 (n = 276); the duration of response was statistically significant in favor of the norgestimate-ethinyl estradiol group in both cases (P < or = .001). The variability of mean percent change in lesions was also statistically significantly greater in the placebo group than in the OC group for total lesions (P < or = .001) and inflammatory lesions (P < or = .001).

CONCLUSION

A triphasic combination of norgestimate and ethinyl estradiol lengthens the time interval to recurrence of acne lesions.

Authors+Show Affiliations

Ortho McNeil Pharmaceutical, Women's Health Care, Raritan, New Jersey 08869, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9920537

Citation

Olson, W H., et al. "The Duration of Response to Norgestimate and Ethinyl Estradiol in the Treatment of Acne Vulgaris." International Journal of Fertility and Women's Medicine, vol. 43, no. 6, 1998, pp. 286-90.
Olson WH, Lippman JS, Robisch DM. The duration of response to norgestimate and ethinyl estradiol in the treatment of acne vulgaris. Int J Fertil Womens Med. 1998;43(6):286-90.
Olson, W. H., Lippman, J. S., & Robisch, D. M. (1998). The duration of response to norgestimate and ethinyl estradiol in the treatment of acne vulgaris. International Journal of Fertility and Women's Medicine, 43(6), 286-90.
Olson WH, Lippman JS, Robisch DM. The Duration of Response to Norgestimate and Ethinyl Estradiol in the Treatment of Acne Vulgaris. Int J Fertil Womens Med. 1998 Nov-Dec;43(6):286-90. PubMed PMID: 9920537.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The duration of response to norgestimate and ethinyl estradiol in the treatment of acne vulgaris. AU - Olson,W H, AU - Lippman,J S, AU - Robisch,D M, PY - 1999/1/27/pubmed PY - 1999/1/27/medline PY - 1999/1/27/entrez SP - 286 EP - 90 JF - International journal of fertility and women's medicine JO - Int J Fertil Womens Med VL - 43 IS - 6 N2 - OBJECTIVE: This was a postmarketing, retrospective, exploratory analysis to investigate the duration of response to a triphasic combination oral contraceptive (OC) (Ortho Tri-Cyclen; Ortho-McNeil Pharmaceutical, Raritan, NJ) [norgestimate-ethinyl estradiol]) in the treatment of moderate acne vulgaris. PROCEDURES: Healthy women with moderate acne vulgaris were enrolled in two 6-month, multicenter, randomized, double-blind, placebo-controlled clinical trials. Subjects received either 3 weeks of active OC treatment (i.e., 0.035 mg ethinyl estradiol plus increasing doses of norgestimate [0.180 mg, 0.215 mg, 0.250 mg]) and 1 week of inactive tablets, or 4 weeks of color-matched placebo tablets. RESULTS: A total of 507 subjects were enrolled in the study. Duration of response was analyzed in subjects with at least slight improvement in global progress of treatment from the earliest cycle showing response (n = 305) and in subjects with at least slight improvement at or before cycle 3 (n = 276); the duration of response was statistically significant in favor of the norgestimate-ethinyl estradiol group in both cases (P < or = .001). The variability of mean percent change in lesions was also statistically significantly greater in the placebo group than in the OC group for total lesions (P < or = .001) and inflammatory lesions (P < or = .001). CONCLUSION: A triphasic combination of norgestimate and ethinyl estradiol lengthens the time interval to recurrence of acne lesions. SN - 1534-892X UR - https://www.unboundmedicine.com/medline/citation/9920537/The_duration_of_response_to_norgestimate_and_ethinyl_estradiol_in_the_treatment_of_acne_vulgaris_ L2 - https://medlineplus.gov/acne.html DB - PRIME DP - Unbound Medicine ER -